The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Biogen boosts gene therapy strategy with Harvard pact focused on inherited eye disease – FierceBiotech
- Hansa Biopharma Gets up to 350M to Make Gene Therapy Work in Resistant… – Labiotech.eu
- FDA Grants Orphan Drug Designation to Neurogene’s Gene Therapy for the Treatment of CLN5 Batten Disease – BioSpace
- Tiny mineral particles are better vehicles for promising gene therapy – ScienceBlog.com
- The Wilderness of Rare Genetic Diseases and the Parents Navigating It – The New York Times
- avast warning for phishing
- the concept of race has no genetic or scientific basis” and that “race is a social concept not a scientific one” (Witt 2010)
- Nanomedicine-Nanotechnology Biology and Medicine
- what happened to jackson avery on greys
- broadcast schedule
- greys anatomy jackson child
- harris silver md
- heroes season 1 claires immortality
- pros and cons of human activity on plants and animals
- higher ed mcat
|Search Immortality Topics:|
Category Archives: Biotechnology
COVID 19 PANDEMIC: Biotechnology Reagents Market is poised to achieve continuing growth During Forecast Period 2020-2026 – Cole of Duty
Global Biotechnology Reagents Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
Biotechnology Reagents Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.
>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Sample
Global Biotechnology Reagents Market is valued at USD 71.25 Billion in 2018 and expected to reach USD 121.06 Billion by 2025 with the CAGR of 7.86% over the forecast period.
Increasing prevalence of diseases such as hepatitis B with growing research and development expenditure bybiotechnologytherapeutics and rising number of biotechnology firms globally are expected to boost the market over the forecast period.
Biotechnology reagents are the substances or compounds used to detect or create an additional substance in order to provide a test reading. Hence, the biotechnologies are used in research fields of genetics, molecular biology, diagnosis, immunology, bioscience and in education. The various uses of biotechnology reagents are; fluorescent microscopy, DNA analysis, immuno phenotyping and cell cycle analysis. The biotechnology reagents industry depends on the growth of biotechnology instrumentation market. Biotechnology reagents market includes technologies such as IVD, PCR, transfection, gene expression and cell culture. The basis of technology market is section into analytical reagents and life science reagents. The Life science technologies include in vitro diagnostics, unit culture, polymerase chain reaction and analytical technologies includes flow cytometry, electrophoresis, mass spectrometry and chromatography. The healthcare biotechnology is usually to improve medicines due to the advantages and pieces of knowledge it provides such as understanding the genetic composition of the human species, foundational structure of hereditary diseases manipulation and repairing of damaged genes to cure diseases. As the researchers might see the engineering of a supercharged flu virus as a perfectly reasonable way to better understand and thus fight the flu, the public might see the drawbacks as equally obvious the virus could escape, or someone could weaponize the research and the advanced genetic tools that some are considering for mosquito control could have unforeseen effects, possibly leading to environmental damage. Although the risks of biotechnology have been fretted over for decades, the increasing pace of progress from low cost DNA sequencing to rapid gene synthesis to precision genome editing suggests biotechnology is entering a new realm of maturity regarding both beneficial relevance and more worrisome risks.
Global Biotechnology Reagents Market report is segmented on the basis of type, application, and by regional & country level. Based on type, global biotechnology reagents market is classified as the Life science and analytical. Based upon application, global biotechnology reagents are classified into protein synthesis and purification, gene expression, DNA and RNA analysis and drug testing.
The regions covered in this biotechnology reagents market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of biotechnology reagents is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Key Players for Global Biotechnology Reagents Market Report-
Some major key players for Global Biotechnology Reagents Market are Life Technologies, Bio-Rad, Thermo Fisher Scientific, Water Corporation, Sigma-Aldrich Agilent Technologies Inc., Beckman Coulter, Roche, Abbott and others.
Global Biotechnology Reagents Market Dynamics
The rapidly increasing use of biotechnology reagents in therapeutics, basic research and its commercialization are the major factors responsible for the growth of this market. According to the World Health Organization (WHO) in 2017, prevalence of hepatitis B estimated about 27 million people 10.5% of all people estimated to be living with hepatitis B were aware of their infection, while 4.5 million around 16.7% of the people diagnosed were on treatment. Hence, the rising prices of DNA sequencing is predictable to serve this sector as a high impact rendering growth is expected to encourage researchers and manufacturers to increase R&D initiatives targeted at understanding genetic variations and developing therapeutic solutions for chronic diseases with large global prevalence such as cardiovascular diseases, diabetes, and cancer. According to the World Health Organization (WHO) in 2015, the estimates that in 257 million people were living with chronic hepatitis B infection as surface antigen positive, the hepatitis B resulted in an estimated 887 000 deaths, mostly from cirrhosis and hepatocellular carcinoma is primary liver cancer. In addition, the high investments in R&D activities, growing biomedical research, increasing number of biotechnology firms and advancement in stem cell research have contributed to the growth of the biotechnology reagents market.
The biotechnology organizations such as the department of biotechnology (DBT) with government funded institutions and other autonomous organizations representing the biotechnology sector, promote funding to support R&D and innovative produce development endeavors. One of the major challenges faced by this market use of biotechnology reagents in the field of drug discovery is an emerging market where proteomics, DNA chips, combinatorial chemistry, and high throughput screening enjoy the spotlight. In addition, high price of biopharmaceuticals may likely to restrain the growth of the biotechnology reagents market. Moreover, increase in the number of biotechnology firms around the globe and increase in research and development expenditure by the biotechnology corporation can provide various opportunities for the further growth of the market. The technological advancements and new product launches in health care and life science industries to life science reagents are an integral part of any clinical diagnostic laboratory and pharmaceutical & biotechnology industry. The recent technological advancements in molecular biology, life sciences, and biotechnology has brought about drastic changes in various fields such as medical diagnostics, drug discovery, personalized medicines, forensic sciences, and clinical research & development of the biotechnology reagents market.
Global Biotechnology Reagents Market Regional Analysis
Geographically,North America dominates the global biotechnology reagents market & incurs the highest expenditure for global R&D. According to the World Health Organization (WHO) in 2018, the chronic diseases in the United States are about 133 million Americans 45% of the population have at least one chronic disease. In addition, rising ongoing research in biological sciences considerable investments by various biotechnology companies and the consistently increasing utilization of biotechnology reagents in the market due to the continuing research and outsourcing activities in the field of life science in this region are also supplementing the market growth.
TheAsia Pacific is expected to show a lucrative growth rate during the forecast period due to increasing research and outsourcing activities in life science field. However, the regionlarge population, presence of emerging economies such as China and India, large number of elderly individuals in Japan presents significant opportunities for global players in these countries. Adoption of technologically advanced products in Japan, China, South Korea, Malaysia, and Singapore are likely to fuel the growth of the life science reagents market in this region. Moreover, increased investment by leading pharmaceutical and biotechnology companies in India and China, and rapidly increasing number of hospitals and diagnostic laboratories in the region boost the growth of the biotechnology reagents market in the region.
Key Benefits for Global Biotechnology Reagents Market Report
Global market report covers in depth historical and forecast analysis.
Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global market report helps to identify opportunities in market place.
Global market report covers extensive analysis of emerging trends and competitive landscape.
By Regional & Country Analysis
Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Methodology
Table of Content:
Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Biotechnology Reagents Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.
Competition by Company: Here, the competition in the Worldwide Global Biotechnology Reagents Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.
Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Biotechnology Reagents Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Biotechnology Reagents Market.
Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Biotechnology Reagents Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.
Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Biotechnology Reagents Market.
Market Forecast: Here, the report offers a complete forecast of the Global Biotechnology Reagents Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.
Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.
We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) the worlds largest science and public advocacy organization, representing 1,000 members announced today that Michelle McMurry-Heath, MD, PhD, will become the organizations next President and CEO on June 1, succeeding former Rep. Jim Greenwood, who has led the organization since 2005.
McMurry-Heath has served in numerous senior leadership roles at Johnson & Johnson (J&J) since 2014. Most recently, as Vice President of External Innovation and Global Leader for Regulatory Science, she led a team of 900 employees charting the evidence generation and regulatory strategy across J&Js medical device companies, specializing in using cutting-edge tools and innovative methods to bring new breakthroughs to patients.
We are living and working through a period in human history when scientific leadership and knowledge are crucial for our organization, our nation and the world, said BIO Chairman Dr. Jeremy Levin, CEO of Ovid Therapeutics. The biotechnology industry is humanitys great hope to speed medical breakthroughs to patients in record time to treat and prevent COVID-19 disease. With her exemplary scientific background, proven federal health policy leadership and track record of driving scientific progress to benefit patients, Michelle is the right person at the right time to lead BIO and the biotech sector into a new future. We welcome her to this new role and are excited to support her efforts to help shape the future of biotechnology. And as Michelle takes over, on behalf of the Board of Directors of BIO, I want to thank Jim Greenwood. Jim is a towering figure and has facilitated immense contributions to patients lives, innovation, our industry and our nation. We owe him a debt of gratitude and look forward to his next steps. I am proud to have worked with him.
As these clarifying times have shown, society will rise or fall on the ingenuity of our scientists, the vibrancy of our innovative ecosystem, and the personal courage of the men and women working day and night to bring cures to patients, food to tables and relief to our environment, McMurry-Heath said. I want scientists, clinicians and innovators to hold their heads high knowing they are addressing the most important issues we face today. BIO represents these everyday heroes and sheroes, and I couldnt be prouder for this opportunity to support their work and shout their message from the rooftop.
Prior to her work at J&J, McMurry-Heath served on the Obama administrations Science Transition Team before being appointed to a scientific leadership role at the U.S. Food and Drug Administrations (FDA) Center for Devices and Radiological Health from 2010 to 2014. During her tenure at FDA, McMurry-Heath was a driving force at the agency, specifically tasked with devising strategies to incorporate the patient perspective into the decision-making process and identifying opportunities for patients to collaborate with innovators.
McMurry-Heath, a Harvard-educated former senior FDA official, is a physician and a molecular immunologist who became the first African-American to graduate from the Duke Medical Scientist Training Program. She served as the founding director of the Aspen Institutes Health Biomedical Science and Society Policy Program focused on broadening access to personalized medicine and bolstering international preparedness for pandemic disease threats.
McMurry-Heath served as a science and technology policy fellow at the American Association for the Advancement of Science. She was also a Robert Wood Johnson Foundation Health and Society Scholar and led health and science policy on Capitol Hill for Senator Joe Lieberman, where she drafted legislation to protect the country from biological attacks. Additionally, she oversaw health policy for the Senators 2004 presidential campaign.
Science matters, now more than ever, Greenwood said. Michelles record of scientific leadership commands attention and respect among policymakers across the world. Michelle has been at the forefront of turning legislative victories into real-world realities for patients whose lives depend on biomedical innovation. Her experience as an innovator, a doer and a bipartisan collaborator will be great assets to BIO and the companies who depend on us to advocate on their behalf. I look forward to handing over BIO to her on June 1st. She will be a great leader.
McMurry-Heath will become just the third leader of BIO since the trade groups 1993 founding. Greenwood, a former six-term Pennsylvania Congressman, became the second leader in BIOs existence following the retirement of founding President Carl Feldbaum, former chief of staff to Senator Arlen Specter (R-PA). Under Greenwoods leadership, BIO has tripled in size. The organization hosts the worlds largest annual biotechnology convention, attracting tens of thousands of individuals from over 70 countries. BIO will hold its 2020 conference (BIO Digital) from June 8 to 12.
In March, BIO launched the Coronavirus Collaboration Initiative, an unprecedented effort among industry to share resources and capabilities to speed the development and delivery of COVID-19 diagnostics, therapeutics and ultimately a vaccine. Many smaller biotech companies have partnered with large biopharmaceutical companies to achieve R&D and manufacturing synergies during the pandemic.
Cellect Biotechnology Announces Positive Data Demonstrating Robust Engraftment Using ApoGraft was Featured in Bone Marrow Transplantation; Primary…
TEL AVIV, Israel, May 11, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'. The article is co-authored by researchers at Cellect and its academic partners.
The paper highlights the pre-clinical research and demonstrates that engraftment is robust following transplantation of treated graft, and the graft retains its immune reconstitution and anti-leukemic effects. The Company has initiated a Phase 1/2 study in adults undergoing stem cell transplant for the treatment of hematological malignancies. The primary endpoint of the study is to evaluate the overall incidence, frequency, and severity of adverse events potentially related to ApoGraft at 180-days post-transplant. All patients transplanted through present time using the ApoGraft process were engrafted and time to engraftment was similar to the standard of care. To date, there have not been any safety and tolerability concerns during the study and patient enrollment is continuing. Both, the principal investigator (PI) and independent data safety monitoring board (DSMB) agree that no serious adverse events (SAEs) reported during the course of the study were related to the ApoGraft process.
The data from the pre-clinical research, and published in this paper, was included in the Company's Investigational New Drug (IND) application, which was approved by the U.S. Food and Drug Administration in late 2019. The Company has received all the necessary approvals to initiate the trial with its academic partner, Washington University, and plans to begin patient recruitment once the COVID-19 pandemic is mitigated and clinics can resume normal practices.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (NASDAQ: APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.
The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.
Forward Looking Statements
This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company's ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.
Cellect Biotechnology Ltd.Eyal Leibovitz, Chief Financial Officerwww.cellect.co+972-9-974-1444
EVC Group LLCMichael Polyvioufirstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/cellect-biotechnology-announces-positive-data-demonstrating-robust-engraftment-using-apograft-was-featured-in-bone-marrow-transplantation-primary-data-points-were-submitted-to-the-fda-during-investigational-new-drug-approval-proc-301056409.html
SOURCE Cellect Biotechnology Ltd.
Company Codes: NASDAQ-SMALL:APOP, TelAviv:APOP
Aviv Regev will follow Michael Varney as Head of Genentech Research and Early Development (gRED) at Roche subsidiary Genentech. Varney will retire from the company at the end of July.
Aviv Regev, currently Chair of the Faculty, Core Institute Member, and member of the Executive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT and Investigator of the Howard Hughes Medical Institute, will join Genentech as the new Head of gRED and will become a member of the enlarged Corporate Executive Committee as of 1 August 2020. She will be based in South San Francisco.
In particular, Regev has pioneered assays for RNA sequencing in single-cells, machine learning algorithms for distilling biological knowledge from the resulting information, and many of the first demonstrations of how to yield foundational new insights into an extraordinarily wide range of molecular circuits, systems, and fields, including immunology, neurobiology, development, inflammatory disease, cancer, and evolution. In doing so, her work is helping to answer the most general of biological questions - how cells and their circuits function and rewire, and how these dynamics underlie health and malfunction in disease.
Aviv Regev has a Ph.D. in computational biology and Master of Science from Tel Aviv University. Through her pioneering efforts she is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and their malfunction in disease.
COVID-19 Testing Kits Market Outlook,Deep Research Report Stydy,Share and perfect Year to Year CAGR Analysis With Forecast Period 2020 to…
Los Angeles, United StatesThe report offers an all-inclusive and accurate research study on the global COVID-19 Testing Kits market while chiefly focusing on current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly benefit from the thorough market analysis provided in the report. The authors of the report have compiled a detailed study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to get a good understanding of future development of the global COVID-19 Testing Kits market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to help with comprehensive evaluation of the global COVID-19 Testing Kits market.
Key companies operating in the global COVID-19 Testing Kits market include : , Beijing Genomics Institute, Zhijiang biology, Sansure, Shanghai Huirui Biotechnology, Geneodx, Shanghai BioGerm Medical Biotechnology, Da An Gene, Wondfo, INNOVITA COVID-19 Testing Kits
Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :
The segmental analysis will help companies to focus on high-growth areas of the global COVID-19 Testing Kits market. In order to broaden the overall understanding of the global COVID-19 Testing Kits industry, the report has segregated the global COVID-19 Testing Kits business into varied segments comprising product type, application, and end user. This examination has been carried out based on parameters like size, CAGR, share, production, and consumption. Also, region-wise assessment, wherein lucrative prospects that a region or country is likely to offer has been explored.
Global COVID-19 Testing Kits Market Segment By Type:
, igM, Others COVID-19 Testing Kits
Global COVID-19 Testing Kits Market Segment By Application:
, igM, Others COVID-19 Testing Kits
It is important for every market participant to be familiar with the competitive scenario in the global COVID-19 Testing Kits industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.
Key companies operating in the global COVID-19 Testing Kits market include : , Beijing Genomics Institute, Zhijiang biology, Sansure, Shanghai Huirui Biotechnology, Geneodx, Shanghai BioGerm Medical Biotechnology, Da An Gene, Wondfo, INNOVITA COVID-19 Testing Kits
Key Questions Answered
Enquire for Customization in this Report: https://www.qyresearch.com/customize-request/form/1700308/global-covid-19-testing-kits-market
Table of Contents
1 Study Coverage1.1 COVID-19 Testing Kits Product Introduction1.2 Market Segments1.3 Key COVID-19 Testing Kits Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global COVID-19 Testing Kits Market Size Growth Rate by Type1.4.2 igM1.4.3 Others1.5 Market by Application1.5.1 Global COVID-19 Testing Kits Market Size Growth Rate by Application1.5.2 Hospital1.5.3 Scientific Research1.5.4 Diagnostic Center1.6 Coronavirus Disease 2019 (Covid-19): COVID-19 Testing Kits Industry Impact1.6.1 How the Covid-19 is Affecting the COVID-19 Testing Kits Industry
184.108.40.206 COVID-19 Testing Kits Business Impact Assessment Covid-19
220.127.116.11 Supply Chain Challenges
18.104.22.168 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and COVID-19 Testing Kits Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19
22.214.171.124 Government Measures to Combat Covid-19 Impact
126.96.36.199 Proposal for COVID-19 Testing Kits Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global COVID-19 Testing Kits Market Size Estimates and Forecasts2.1.1 Global COVID-19 Testing Kits Revenue 2015-20262.1.2 Global COVID-19 Testing Kits Sales 2015-20262.2 COVID-19 Testing Kits Market Size by Region: 2020 Versus 20262.2.1 Global COVID-19 Testing Kits Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global COVID-19 Testing Kits Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global COVID-19 Testing Kits Competitor Landscape by Players3.1 COVID-19 Testing Kits Sales by Manufacturers3.1.1 COVID-19 Testing Kits Sales by Manufacturers (2015-2020)3.1.2 COVID-19 Testing Kits Sales Market Share by Manufacturers (2015-2020)3.2 COVID-19 Testing Kits Revenue by Manufacturers3.2.1 COVID-19 Testing Kits Revenue by Manufacturers (2015-2020)3.2.2 COVID-19 Testing Kits Revenue Share by Manufacturers (2015-2020)3.2.3 Global COVID-19 Testing Kits Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by COVID-19 Testing Kits Revenue in 20193.2.5 Global COVID-19 Testing Kits Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 COVID-19 Testing Kits Price by Manufacturers3.4 COVID-19 Testing Kits Manufacturing Base Distribution, Product Types3.4.1 COVID-19 Testing Kits Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers COVID-19 Testing Kits Product Type3.4.3 Date of International Manufacturers Enter into COVID-19 Testing Kits Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global COVID-19 Testing Kits Market Size by Type (2015-2020)4.1.1 Global COVID-19 Testing Kits Sales by Type (2015-2020)4.1.2 Global COVID-19 Testing Kits Revenue by Type (2015-2020)4.1.3 COVID-19 Testing Kits Average Selling Price (ASP) by Type (2015-2026)4.2 Global COVID-19 Testing Kits Market Size Forecast by Type (2021-2026)4.2.1 Global COVID-19 Testing Kits Sales Forecast by Type (2021-2026)4.2.2 Global COVID-19 Testing Kits Revenue Forecast by Type (2021-2026)4.2.3 COVID-19 Testing Kits Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global COVID-19 Testing Kits Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global COVID-19 Testing Kits Market Size by Application (2015-2020)5.1.1 Global COVID-19 Testing Kits Sales by Application (2015-2020)5.1.2 Global COVID-19 Testing Kits Revenue by Application (2015-2020)5.1.3 COVID-19 Testing Kits Price by Application (2015-2020)5.2 COVID-19 Testing Kits Market Size Forecast by Application (2021-2026)5.2.1 Global COVID-19 Testing Kits Sales Forecast by Application (2021-2026)5.2.2 Global COVID-19 Testing Kits Revenue Forecast by Application (2021-2026)5.2.3 Global COVID-19 Testing Kits Price Forecast by Application (2021-2026) 6 North America6.1 North America COVID-19 Testing Kits by Country6.1.1 North America COVID-19 Testing Kits Sales by Country6.1.2 North America COVID-19 Testing Kits Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America COVID-19 Testing Kits Market Facts & Figures by Type6.3 North America COVID-19 Testing Kits Market Facts & Figures by Application 7 Europe7.1 Europe COVID-19 Testing Kits by Country7.1.1 Europe COVID-19 Testing Kits Sales by Country7.1.2 Europe COVID-19 Testing Kits Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe COVID-19 Testing Kits Market Facts & Figures by Type7.3 Europe COVID-19 Testing Kits Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific COVID-19 Testing Kits by Region8.1.1 Asia Pacific COVID-19 Testing Kits Sales by Region8.1.2 Asia Pacific COVID-19 Testing Kits Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific COVID-19 Testing Kits Market Facts & Figures by Type8.3 Asia Pacific COVID-19 Testing Kits Market Facts & Figures by Application 9 Latin America9.1 Latin America COVID-19 Testing Kits by Country9.1.1 Latin America COVID-19 Testing Kits Sales by Country9.1.2 Latin America COVID-19 Testing Kits Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America COVID-19 Testing Kits Market Facts & Figures by Type9.3 Central & South America COVID-19 Testing Kits Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa COVID-19 Testing Kits by Country10.1.1 Middle East and Africa COVID-19 Testing Kits Sales by Country10.1.2 Middle East and Africa COVID-19 Testing Kits Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa COVID-19 Testing Kits Market Facts & Figures by Type10.3 Middle East and Africa COVID-19 Testing Kits Market Facts & Figures by Application 11 Company Profiles11.1 Beijing Genomics Institute11.1.1 Beijing Genomics Institute Corporation Information11.1.2 Beijing Genomics Institute Description, Business Overview and Total Revenue11.1.3 Beijing Genomics Institute Sales, Revenue and Gross Margin (2015-2020)11.1.4 Beijing Genomics Institute COVID-19 Testing Kits Products Offered11.1.5 Beijing Genomics Institute Recent Development11.2 Zhijiang biology11.2.1 Zhijiang biology Corporation Information11.2.2 Zhijiang biology Description, Business Overview and Total Revenue11.2.3 Zhijiang biology Sales, Revenue and Gross Margin (2015-2020)11.2.4 Zhijiang biology COVID-19 Testing Kits Products Offered11.2.5 Zhijiang biology Recent Development11.3 Sansure11.3.1 Sansure Corporation Information11.3.2 Sansure Description, Business Overview and Total Revenue11.3.3 Sansure Sales, Revenue and Gross Margin (2015-2020)11.3.4 Sansure COVID-19 Testing Kits Products Offered11.3.5 Sansure Recent Development11.4 Shanghai Huirui Biotechnology11.4.1 Shanghai Huirui Biotechnology Corporation Information11.4.2 Shanghai Huirui Biotechnology Description, Business Overview and Total Revenue11.4.3 Shanghai Huirui Biotechnology Sales, Revenue and Gross Margin (2015-2020)11.4.4 Shanghai Huirui Biotechnology COVID-19 Testing Kits Products Offered11.4.5 Shanghai Huirui Biotechnology Recent Development11.5 Geneodx11.5.1 Geneodx Corporation Information11.5.2 Geneodx Description, Business Overview and Total Revenue11.5.3 Geneodx Sales, Revenue and Gross Margin (2015-2020)11.5.4 Geneodx COVID-19 Testing Kits Products Offered11.5.5 Geneodx Recent Development11.6 Shanghai BioGerm Medical Biotechnology11.6.1 Shanghai BioGerm Medical Biotechnology Corporation Information11.6.2 Shanghai BioGerm Medical Biotechnology Description, Business Overview and Total Revenue11.6.3 Shanghai BioGerm Medical Biotechnology Sales, Revenue and Gross Margin (2015-2020)11.6.4 Shanghai BioGerm Medical Biotechnology COVID-19 Testing Kits Products Offered11.6.5 Shanghai BioGerm Medical Biotechnology Recent Development11.7 Da An Gene11.7.1 Da An Gene Corporation Information11.7.2 Da An Gene Description, Business Overview and Total Revenue11.7.3 Da An Gene Sales, Revenue and Gross Margin (2015-2020)11.7.4 Da An Gene COVID-19 Testing Kits Products Offered11.7.5 Da An Gene Recent Development11.8 Wondfo11.8.1 Wondfo Corporation Information11.8.2 Wondfo Description, Business Overview and Total Revenue11.8.3 Wondfo Sales, Revenue and Gross Margin (2015-2020)11.8.4 Wondfo COVID-19 Testing Kits Products Offered11.8.5 Wondfo Recent Development11.9 INNOVITA11.9.1 INNOVITA Corporation Information11.9.2 INNOVITA Description, Business Overview and Total Revenue11.9.3 INNOVITA Sales, Revenue and Gross Margin (2015-2020)11.9.4 INNOVITA COVID-19 Testing Kits Products Offered11.9.5 INNOVITA Recent Development11.1 Beijing Genomics Institute11.1.1 Beijing Genomics Institute Corporation Information11.1.2 Beijing Genomics Institute Description, Business Overview and Total Revenue11.1.3 Beijing Genomics Institute Sales, Revenue and Gross Margin (2015-2020)11.1.4 Beijing Genomics Institute COVID-19 Testing Kits Products Offered11.1.5 Beijing Genomics Institute Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 COVID-19 Testing Kits Market Estimates and Projections by Region12.1.1 Global COVID-19 Testing Kits Sales Forecast by Regions 2021-202612.1.2 Global COVID-19 Testing Kits Revenue Forecast by Regions 2021-202612.2 North America COVID-19 Testing Kits Market Size Forecast (2021-2026)12.2.1 North America: COVID-19 Testing Kits Sales Forecast (2021-2026)12.2.2 North America: COVID-19 Testing Kits Revenue Forecast (2021-2026)12.2.3 North America: COVID-19 Testing Kits Market Size Forecast by Country (2021-2026)12.3 Europe COVID-19 Testing Kits Market Size Forecast (2021-2026)12.3.1 Europe: COVID-19 Testing Kits Sales Forecast (2021-2026)12.3.2 Europe: COVID-19 Testing Kits Revenue Forecast (2021-2026)12.3.3 Europe: COVID-19 Testing Kits Market Size Forecast by Country (2021-2026)12.4 Asia Pacific COVID-19 Testing Kits Market Size Forecast (2021-2026)12.4.1 Asia Pacific: COVID-19 Testing Kits Sales Forecast (2021-2026)12.4.2 Asia Pacific: COVID-19 Testing Kits Revenue Forecast (2021-2026)12.4.3 Asia Pacific: COVID-19 Testing Kits Market Size Forecast by Region (2021-2026)12.5 Latin America COVID-19 Testing Kits Market Size Forecast (2021-2026)12.5.1 Latin America: COVID-19 Testing Kits Sales Forecast (2021-2026)12.5.2 Latin America: COVID-19 Testing Kits Revenue Forecast (2021-2026)12.5.3 Latin America: COVID-19 Testing Kits Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa COVID-19 Testing Kits Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: COVID-19 Testing Kits Sales Forecast (2021-2026)12.6.2 Middle East and Africa: COVID-19 Testing Kits Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: COVID-19 Testing Kits Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key COVID-19 Testing Kits Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 COVID-19 Testing Kits Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.
CFIUS and Critical Technologies: Implications for the Biotechnology and Life Sciences Sector – JD Supra
Updated: May 25, 2018:
JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).
Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:
Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.
Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.
We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:
JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at email@example.com.
Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.
Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.
JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.
You can make a request to exercise any of these rights by emailing us at firstname.lastname@example.org or by writing to us at:
You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.
We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.
Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.
You can make a request for this information by emailing us at email@example.com or by writing to us at:
Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.
For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to firstname.lastname@example.org. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to email@example.com.
As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.
There are different types of cookies and other technologies used our Website, notably:
JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.
Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:
Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.
The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.